Opportunity Information: Apply for PAR 22 099
The Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) opportunity (Funding Opportunity Number PAR-22-099) is a National Institutes of Health (NIH) discretionary grant designed to push forward next-generation, biomimetic tissue-engineered platforms that can be used to study cancer in more realistic and experimentally useful ways. The central idea is to fund projects that build and thoroughly characterize in vitro and ex vivo engineered systems that better recreate the biology of tumors as they behave in the body, rather than relying only on traditional cell culture models that often miss key features of the tumor microenvironment. Applications are expected to be driven by a clear, testable cancer research hypothesis, meaning the engineering work is not meant to be purely technological for its own sake, but instead tightly connected to answering important biological questions about cancer.
A defining feature of this FOA is its emphasis on genuinely collaborative, multidisciplinary teams. NIH is explicitly looking for projects that bridge cancer biology with fields like regenerative medicine, tissue engineering, biomaterials, and bioengineering. In practice, that means proposals should show integrated expertise across these domains to develop experimental models that mimic cancer pathophysiology, such as engineered tumor tissues, microenvironment-mimicking scaffolds, organotypic cultures, or other biomimetic constructs that allow researchers to probe cancer phenomena in controlled, measurable conditions. A major expectation is strong characterization of the developed systems, since the point of the program is not only to invent new platforms but also to make them credible, reproducible, and scientifically interpretable as cancer research tools.
Funded projects will be part of a larger coordinated effort called the Cancer Tissue Engineering Collaborative (TEC) Research Program. Through this program structure, the NIH aims to (1) accelerate the development and maturation of innovative, well-characterized in vitro and ex vivo systems that cancer researchers can use, (2) broaden the availability and relevance of these systems across multiple cancer types, and (3) encourage deeper investigation of cancer behaviors using biomimetic, tissue-engineered technologies. In other words, the program is meant to create a portfolio of complementary engineered model systems and to promote their use for studying tumor biology in settings that more closely reflect human disease, helping close the gap between simplified lab models and the complexity seen in patients.
The award mechanism is an R01, with clinical trials listed as optional, which generally means applicants may propose clinical trial components only if they are appropriate and justified for the proposed research, but a clinical trial is not required. The funding activity categories listed for this opportunity are Education and Health, and the associated CFDA numbers include 93.393, 93.394, 93.395, 93.396, and 93.399, which align with NIH cancer-related and biomedical research assistance programs.
Eligibility is broad and includes many organization types that commonly apply for NIH research grants. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status (in both cases, other than institutions of higher education); for-profit organizations (other than small businesses) and small businesses; and other entities. The FOA also explicitly notes additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations.
Key administrative details included in the source data are that the opportunity was created on 2022-01-21 and lists an original closing date of 2025-05-07. The source data also lists an award ceiling of 40,000, although NIH R01 budgets are often determined by program and application specifics and may not always be represented consistently in summary feeds; applicants typically confirm budget expectations directly in the FOA text and NIH policy guidance when preparing an application.Apply for PAR 22 099
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396, 93.399.
- This funding opportunity was created on 2022-01-21.
- Applicants must submit their applications by 2025-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $40,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: PAR-22-099 - The Cancer Tissue Engineering Collaborative (TEC) (R01 Clinical Trial Optional)
What is the PAR-22-099 funding opportunity?
PAR-22-099 is a National Institutes of Health (NIH) discretionary grant opportunity titled "The Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)." It supports research projects that develop and rigorously characterize biomimetic, tissue-engineered platforms for cancer research.
What is the main purpose of this opportunity?
The purpose is to accelerate next-generation in vitro and ex vivo engineered systems that more realistically recreate tumor biology and the tumor microenvironment than traditional cell culture models. The goal is to enable cancer research that is more experimentally useful and biologically relevant to how tumors behave in the body.
What types of model systems does NIH want to fund under this FOA?
Projects are expected to create biomimetic tissue-engineered technologies such as engineered tumor tissues, microenvironment-mimicking scaffolds, organotypic cultures, and other in vitro or ex vivo constructs designed to mimic cancer pathophysiology in controlled and measurable ways.
Are purely technology-development projects allowed?
Based on the description provided, applications are expected to be driven by a clear, testable cancer research hypothesis. This indicates the engineering is not intended to be technology development for its own sake, but tightly connected to answering important biological questions about cancer.
What is emphasized regarding validation and characterization of the engineered systems?
A major expectation is strong characterization of the developed systems. The FOA highlights that the program is not only about inventing new platforms, but also about making them credible, reproducible, and scientifically interpretable as tools for cancer research.
What does "Cancer Tissue Engineering Collaborative (TEC) Research Program" mean in practice?
Funded projects become part of a larger coordinated effort called the Cancer Tissue Engineering Collaborative (TEC) Research Program. The NIH intends this program to build a portfolio of complementary engineered model systems and promote their use for studying tumor biology in settings that more closely reflect human disease.
What are the stated goals of the TEC Research Program?
The description identifies three overarching aims: (1) accelerate development and maturation of innovative, well-characterized in vitro and ex vivo systems cancer researchers can use; (2) broaden availability and relevance of these systems across multiple cancer types; and (3) encourage deeper investigation of cancer behaviors using biomimetic, tissue-engineered technologies.
What grant mechanism is used for this opportunity?
The award mechanism is an NIH R01.
Are clinical trials required?
No. Clinical trials are listed as optional, meaning a clinical trial component may be proposed only if appropriate and justified for the research, but a clinical trial is not required.
What kinds of expertise and teams does NIH expect?
The FOA places strong emphasis on genuinely collaborative, multidisciplinary teams. Proposals are expected to bridge cancer biology with fields such as regenerative medicine, tissue engineering, biomaterials, and bioengineering, demonstrating integrated expertise across these domains.
What research gap is this FOA trying to address?
The FOA aims to help close the gap between simplified lab models (such as traditional cell culture) and the complexity seen in patients by supporting biomimetic engineered models that better capture key features of tumor biology and the tumor microenvironment.
What are the funding activity categories listed for this opportunity?
The funding activity categories listed are Education and Health.
Which CFDA numbers are associated with this NIH opportunity?
The associated CFDA numbers listed are 93.393, 93.394, 93.395, 93.396, and 93.399.
Who is eligible to apply?
Eligibility is broad and includes many organization types that commonly apply for NIH research grants, including:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Tribal organizations that are not federally recognized
- Public housing authorities and Indian housing authorities
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
- Other entities
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA explicitly notes additional eligible applicant categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
Can federal agencies apply?
Yes. Eligible federal agencies are explicitly included among additional eligible applicant categories in the information provided.
Are U.S. territories and non-U.S. organizations eligible?
Yes. The eligibility list explicitly includes U.S. territories or possessions and non-U.S. (foreign) organizations.
When was this opportunity created?
The source data lists the opportunity as created on 2022-01-21.
What is the closing date shown in the provided information?
The source data lists an original closing date of 2025-05-07.
Is there an award ceiling listed, and how should it be interpreted?
The source data lists an award ceiling of 40,000. However, the provided information also notes that NIH R01 budgets are often determined by program and application specifics and may not always be represented consistently in summary feeds. Applicants typically confirm budget expectations directly in the FOA text and NIH policy guidance when preparing an application.
Does this FOA focus on specific cancer types?
The program description emphasizes broadening the availability and relevance of these engineered systems across multiple cancer types, suggesting interest in approaches that can support research beyond a single narrow context.
What is the expected scientific orientation of proposed work?
Applications are expected to be hypothesis-driven and designed to probe cancer phenomena using biomimetic, tissue-engineered models in controlled, measurable conditions, with substantial emphasis on characterization and interpretability of the resulting platforms.
Browse more opportunities from the same category: Education, Health
Next opportunity: FY2022 Research and Development for Next Generation Nuclear Physics Accelerator Facilities
Previous opportunity: HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 22 099
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 22 099) also looked into and applied for these:
| Funding Opportunity |
|---|
| Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed) Apply for PAR 22 058 Funding Number: PAR 22 058 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Evaluating the Impact of COVID-19 Pandemic-related Food and Housing Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional) Apply for RFA NR 22 001 Funding Number: RFA NR 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional) Apply for RFA MH 22 130 Funding Number: RFA MH 22 130 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed) Apply for RFA NS 22 035 Funding Number: RFA NS 22 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Data, Evaluation and Coordinating Center for: A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) (U24 Clinical Trial Not Allowed) Apply for RFA CA 22 014 Funding Number: RFA CA 22 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional) Apply for RFA DA 23 003 Funding Number: RFA DA 23 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Apply for PAR 22 086 Funding Number: PAR 22 086 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) Apply for PAR 22 085 Funding Number: PAR 22 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) Apply for PAR 22 114 Funding Number: PAR 22 114 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required) Apply for RFA DA 23 007 Funding Number: RFA DA 23 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required) Apply for RFA DA 23 006 Funding Number: RFA DA 23 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional) Apply for RFA CA 22 015 Funding Number: RFA CA 22 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) Apply for PAR 22 123 Funding Number: PAR 22 123 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed) Apply for RFA HL 23 007 Funding Number: RFA HL 23 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed) Apply for RFA DA 23 009 Funding Number: RFA DA 23 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional) Apply for RFA DA 23 010 Funding Number: RFA DA 23 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Short-Term Research Education Experiences to Attract Talented Students to Biomedical Informatics/Data Science Careers and Enhance Diversity (R25 Clinical Trial Not Allowed) Apply for RFA LM 22 001 Funding Number: RFA LM 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) Apply for PAR 22 133 Funding Number: PAR 22 133 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 - Clinical Trial Not Allowed) Apply for RFA DA 23 004 Funding Number: RFA DA 23 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) Apply for RFA DA 23 014 Funding Number: RFA DA 23 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 22 099", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.